Cell & Gene State of the Industry Briefing

ARM’s hybrid 2023 Cell & Gene State of the Industry Briefing attracted over 800+ key stakeholders in the field. This event included ARM’s annual yearly update on the sector’s progress followed by two panel sessions featuring top CEOs and executives highlighting future inflection points for cell and gene therapies in the coming year.

Who Attends?

Over 800 of the cell and gene therapy field’s top stakeholders including company founders, C-level business executives, investors, media, patient advocates and academic leaders interested in learning more on the sector’s recent advances and outlook for the industry in the coming year.

View the 2023 Cell & Gene State of the Industry Briefing

Introduction & Industry Update

Tim Hunt, CEO, Alliance for Regenerative Medicine

Download the presentation slides here.

An Update on Gene Therapy Commercialization

Devyn Smith, Ph.D., CEO, Arbor Biotechnologies; Chairman, Alliance for Regenerative Medicine (Moderator)
Derek Hicks, Chief Business Officer, Intellia Therapeutics
Matt Kapusta, CEO, uniQure
Suma Krishnan, Founder and Chief Operating Officer, Krystal Biotech

Cell Therapy Milestones in 2023

Melissa Carpenter, Ph.D., Chief Scientific Officer, Regenerative Medicine, ElevateBio (Moderator)
Abigail Jenkins, President and CEO, Gamida Cell
Adrian Rawcliffe, CEO, Adaptimmune Therapeutics
Pascal Touchon, President and CEO, Atara Biotherapeutics

In Partnership With:

Questions?
Please contact Jancee Curl at jcurl@alliancerm.org.